$CTRI

Centuri Holdings (CTRI) director reports RSU vesting and new equity grant

Centuri Holdings director Charles R. Patton reported recent equity compensation activities. On May 18, 2026, 7,338 Restricted Stock Units (RSUs) granted in 2025 vested and converted into common shares. The following day, May 19, 2026, Patton received a new grant of 4,067 RSUs. Following these transactions, Charles R. Patton directly holds 29,309 shares of Centuri Holdings common stock.

Original reporting
Published May 21, 2026, 4:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 21, 2026, 5:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CTRI
Neutral
medium confidence
Mentioned
$CTRI
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$CTRINeutralMed
01

Why it matters

While insider activity can signal confidence, it should be corroborated with broader market and company fundamentals for reliable trading decisions.

02

Market read

The news is highly relevant to CTRI shareholders and traders focusing on company-specific events.

03

What to watch

Market conditions, overall industry trends, and company fundamentals should be considered before acting on insider activity.

Relevance 6/10Timing: High, as the recent transactions occurred within the last few days.

Background

Centuri Holdings' insider, Charles R. Patton, has reported recent RSU vesting and a new grant, reflecting ongoing compensation and potential confidence in the company's prospects.

Company-level read

Ticker impact

$CTRINeutralMedium confidence
Context

The news pertains directly to the insider trading activity of Centuri Holdings (CTRI).

Expected impact

Potential slight upward movement in the short term, approximately 2-3%.

Evidence & confidence

Insider transactions often reflect management's confidence but are not definitive indicators of future performance. The recent RSU vesting and new grant suggest ongoing commitment, which could support stock appreciation.

Market effects

The activity is specific to Centuri Holdings and does not suggest broader sector implications.

Limited regional impact, as the activity is company-specific.

Negligible, as the news pertains solely to insider activity of a single company.

Counterpoint

Insider activity may be routine and not indicative of future performance; stock could remain flat or decline.

Key entities

  • Charles R. Patton

    Director of Centuri Holdings involved in recent equity transactions.

  • Centuri Holdings

    The subject of the insider trading activity and stock performance.

Related articles

$CTRIHigh

CENTURI REPORTS SECOND QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 GUIDANCE

Centuri Holdings, Inc. (CTRI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Contacts: For Centuri investors, contact: For Centuri media information, contact: Nate Tetlow Jennifer Russo (480) 851-8426 (602) 781-6958 Ntetlow@centuri.com JRusso@Centuri.com FOR IMMEDIATE RELEASE August 4, 2026 CENTURI REPORTS SECOND QUARTER 2026 RE

$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.

$RKLBMed

Rocket Lab Just Signed the Biggest Commercial Electron Deal in Its History. Its Launch Backlog Now Tops 100.

Rocket Lab (RKLB) secured a 20-launch deal with Synspective, its largest commercial contract, boosting its backlog to over 100 missions. Synspective's total orders now reach 47 Electron missions. The stock rose 6% post-announcement, but concerns about competition from SpaceX persist. Rocket Lab's revenue per launch increased to $9.2M in H1 2026, with costs dropping to $4.9M.